AnalystsKaveri PohlmanKaveri Pohlman's Stock Forecasts
AnalystsKaveri Pohlman
Sectors:
Industries:
Analyst Ranking
Bottom 5%
#4856 out of 5092 analysts
Average Return
-8.22%
Win Rate
30%9 out of 30
Risk vs Reward
Poor
Good
Kaveri Pohlman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Checkmate Pharmaceuticals IncCMPI | +222.67% | $3.22 | $10.39 | 2022-03-29 - 2022-04-20 | Strong Buy |
Ambrx Biopharma IncAMAM | +137.69% | $11.78 | $28.00 | 2023-09-11 - 2024-03-06 | Strong Buy |
Ventyx Biosciences IncVTYX | +128.61% | $3.60 | $8.23 | 2025-09-30 - 2025-11-03 | Strong Buy |
Macrogenics IncMGNX | +116.15% | $7.12 | $15.39 | 2023-03-20 - 2024-03-20 | Strong Buy |
Oruka Therapeutics IncORKA | +61.57% | $16.21 | $26.19 | 2025-09-16 - 2025-11-03 | Strong Buy |
Kaveri Pohlman Analyst Color
Get additional color on Kaveri Pohlman's coverage of popular stocks
Kaveri Pohlman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Sagimet Biosciences IncSGMT | 1 | Strong Buy | $29.00 | +259.80% | Initiates Coverage On | 13 days ago |
Rapt Therapeutics IncRAPT | 2 | Strong Buy | $60.00 | +104.43% | Maintains | 14 days ago |
Ventyx Biosciences IncVTYX | 1 | Strong Buy | $11.00 | +33.66% | Initiates Coverage On | a month ago |
Oruka Therapeutics IncORKA | 1 | Strong Buy | $46.00 | +75.64% | Maintains | 2 months ago |
Arrivent Biopharma IncAVBP | 1 | Strong Buy | $32.00 | +81.82% | Initiates Coverage On | 4 months ago |
Genmab AGMAB | 3 | Strong Buy | $47.00 | N/A | Maintains | a year ago |
Macrogenics IncMGNX | 3 | Strong Buy | $9.00 | N/A | Maintains | a year ago |
Cullinan Therapeutics IncCGEM | 2 | Strong Buy | $30.00 | N/A | Maintains | 2 years ago |
Xencor IncXNCR | 1 | Strong Buy | $38.00 | N/A | Maintains | 2 years ago |
Nuvation Bio IncNUVB | 2 | Strong Buy | $5.00 | N/A | Upgrades | 2 years ago |
Janux Therapeutics IncJANX | 1 | Strong Buy | $62.00 | N/A | Initiates Coverage On | 2 years ago |
Pyxis Oncology IncPYXS | 1 | Strong Buy | $8.00 | N/A | Initiates Coverage On | 2 years ago |
Exelixis IncEXEL | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | 2 years ago |
Ambrx Biopharma IncAMAM | 1 | Strong Buy | $26.00 | N/A | Initiates Coverage On | 2 years ago |
Arcus Biosciences IncRCUS | 1 | Strong Buy | $70.00 | N/A | Reiterates | 2 years ago |
Oncosec Medical IncONCSQ | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Shattuck Labs IncSTTK | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 3 years ago |
Cytomx Therapeutics IncCTMX | 2 | Strong Buy | $8.00 | N/A | Maintains | 3 years ago |
Neximmune IncNEXI | 1 | Strong Buy | $125.00 | N/A | Initiates Coverage On | 3 years ago |
Checkmate Pharmaceuticals IncCMPI | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Oncternal Therapeutics IncONCT | 1 | Strong Buy | $100.00 | N/A | Initiates Coverage On | 4 years ago |
Sonnet Biotherapeutics Holdings IncSONN | 2 | Strong Buy | $4,928.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.